Tocilizumab fails to improve condition of severe Covid-19 patients
Posted by
www.biotecnika.org
The result of the COVACTA study dashes the hopes of experts who were
looking to use the rheumatoid arthritis drug as treatment option for
Covid-19 patients. Tocilizumab is sold by Roche under the brand
Acetmra.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/tocilizumab-fails-to-improve-condition-of-severe-covid-19-patients/articleshow/77245090.cms
Subscribe to:
Post Comments (Atom)
Post a Comment